Wednesday, February 3, 2021
BIOL News
| ID | stock | broker | amount | AVG | BUY TOTAL | date | time | Filled price | amount filled | volume | Total filled | total Stock | Total $ | final price | Remark |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 53 | BIOL | TD | 40 | $25.85 | $1,033.97 | 9/2/2022 | $1.37 | 4,000.00 | 0 | $5,480.00 | 4040 | $6,513.97 | $1.61 |
Biolase gains after forecasting strong near-term outlook
BIOLASE (NASDAQ:BIOL) has climbed ~25.0% in the post-market after the company exceeded analyst expectations with its Q2 2021 financials and provided a solid outlook for the current quarter,
Second-quarter revenue has risen ~211% YoY to $9.1M, indicating an improvement of ~6% from the pre-pandemic level.
Net loss narrowed to $702K from $4.7M a year ago as gross margin expanded by 1,200bps from the previous year to ~44%. Meanwhile, the cash and equivalents stood at $37.1M, more than double the level at the end of 2020.
Q3 2021, the weakest quarter seasonally, is expected to generate the same level of revenue for the company as the second quarter of 2021, according to projections from Biolase (BIOL). However, the consensus Q3 2021 estimates for Biolase stands at $8.9M.
Now read: Biolase EPS beats by $0.04, beats on revenue
RH net loss104 avg1.03(3000sh) 15 March 2020
As of today 02/23/2021 Biol was down til 0.75 highest is
Stocks: Profile
Based on 1 analyst offering 12 month price targets for Biolase in the last 3 months. The average price target is $2.00 with a high forecast of $2.00 and a low forecast of $2.00. The average price target represents a 69.49% increase from the last price of $1.18.
OGEN (14/01/2021 ) event the prices is up - OGEN news
| January 14, 2021 | ||
|---|---|---|
*Oragenics shares are trading higher after the company issued a letter to shareholders highlighting updates regarding development of its COVID-19 vaccine, Terra CoV-2.(Benzinga) | ||
Oragenics Issues Letter To Stockholders(Benzinga) | ||
Oragenics news 02/02/2021
*Oragenics Announces Spike Protein Cov-2 S-2P Created By The NIH And Licensed By The Company Demonstrates Protective Immunity In Immunized Mice Challenged With Mouse-adapted Sars-CoV-2 Virus(Benzinga) | ||
ROCE Insights For Corbus Pharmaceuticals-news ( 02/02/2021 )
ROCE Insights For Corbus Pharmaceuticals
10:44 am ET February 2, 2021 (Benzinga) Print
During Q3, Corbus Pharmaceuticals (NASDAQ:CRBP) brought in sales totaling $1.23 million. However, earnings decreased 10.92%, resulting in a loss of $33.97 million. Corbus Pharmaceuticals collected $286.35 thousand in revenue during Q2, but reported earnings showed a $38.14 million loss.
Why ROCE Is Significant
Changes in earnings and sales indicate shifts in Corbus Pharmaceuticals's Return on Capital Employed, a measure of yearly pre-tax profit relative to capital employed by a business
. Generally, a higher ROCE suggests successful growth of a company and is a sign of higher earnings per share in the future. In Q3, Corbus Pharmaceuticals posted an ROCE of -1.16%.
It is important to keep in mind ROCE evaluates past performance and is not used as a predictive tool. It is a good measure of a company's recent performance, but several factors could affect earnings and sales in the near future.
ROCE is an important metric for the comparison of similar companies. A relatively high ROCE shows Corbus Pharmaceuticals is potentially operating at a higher level of efficiency than other companies in its industry.
If the company is generating high profits with its current level of capital, some of that money can be reinvested in more capital which will generally lead to higher returns and earnings per share growth.
In Corbus Pharmaceuticals's case, the ROCE ratio shows the amount of assets may not be helping the company achieve higher returns. Investors may take this into account before making any long-term financial decisions.
Q3 Earnings Insight
Corbus Pharmaceuticals reported Q3 earnings per share at $-0.43/share, which did not meet analyst predictions of $-0.42/share.
© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Subscribe to:
Posts (Atom)